Skip to main content

Month: February 2024

Augmedix to Participate in Citizens JMP Technology Conference

SAN FRANCISCO, Feb. 27, 2024 (GLOBE NEWSWIRE) — Augmedix, Inc. (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that members of its management team will participate in a fireside chat and host investor meetings at the Citizens JMP Technology Conference taking place in San Francisco on March 4, 2024. The fireside chat will be held at 11 a.m. PT / 2 p.m. ET. The webcast can be accessed live or as an archived replay on the Company’s Investor Relations website at https://ir.augmedix.com/. Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please submit a request on the conference website, contact your Citizens JMP representative, or email Augmedix’s IR team FNK IR at investors@augmedix.com. About...

Continue reading

Company Generates Record Subscriptions Sales for 2023 Holiday Season

Karaoke Subscription Service Generated $3.28 Million in Sales, 35% Increase Year-Over-Year Fort Lauderdale, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) — The Singing Machine Company, Inc. (“Singing Machine” or “the Company”) (NASDAQ: MICS) – the worldwide leader in consumer karaoke products, today announced a significant new milestone in its partnership with leading music, media and technology company, Stingray Group, Inc. (“Stingray”), for their shared karaoke subscription service. For 2023, the Stingray-Singing Machine subscription service generated a record $3.28 million in gross sales, representing a 34.8% increase over the prior calendar year subscription sales. As part of its agreement with Stingray, the Company’s profit share is calculated after deducting all costs of goods sold (COGS) and expenses associated with maintaining this...

Continue reading

Malibu Boats, Inc. to Participate at the Raymond James 2024 Institutional Investors Conference

LOUDON, Tenn., Feb. 27, 2024 (GLOBE NEWSWIRE) — Malibu Boats, Inc. (Nasdaq: MBUU) announced today that Jack Springer, Malibu’s Chief Executive Officer, will participate in a fireside chat at the Raymond James 2024 Institutional Investors Conference at the JW Marriott Grande Lakes in Orlando, Florida. The fireside chat is scheduled for 11:35 a.m. Eastern Time on Tuesday, March 5, 2024. An audio webcast of the presentation will be available by accessing the Malibu Boats Investor website at investors.malibuboats.com. A replay of the webcast will be available for 90 days following the event. About Malibu Boats, Inc. Based in Loudon, Tennessee, Malibu Boats, Inc. (MBUU) is a leading designer, manufacturer and marketer of a diverse range of recreational powerboats, including performance sport, sterndrive and outboard boats. Malibu Boats,...

Continue reading

Marimaca to Present at the BMO 2024 Global Metals, Mining and Critical Minerals Conference – Live Webinar

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Marimaca Copper Corp. (“Marimaca Copper” or the “Company”) (TSX: MARI) announces that Hayden Locke, President & CEO, will be presenting at the 2024 BMO Global Metals, Mining and Critical Minerals Conference on Tuesday, February 27th 2024 at 5:00pm Eastern Time. The presentation will highlight the Company’s progress at the Marimaca Project toward the Definitive Feasibility Study as well as the Company’s regional exploration strategy. A live stream of the presentation will be available at the link below. Webcast Link (Tuesday, February 27th, 2024, 5:00pm ET) Contact InformationFor further information please visit www.marimaca.com or contact: Tavistock +44 (0) 207 920 3150Emily Moss / Adam Baynesmarimaca@tavistock.co.uk Forward Looking Statements This news release...

Continue reading

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, Mar. 5, at 2:50 p.m. EDT (11:50 a.m. PDT) in Boston, Massachusetts. A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event. About Bolt Biotherapeutics, Inc.Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid...

Continue reading

Refined Metals Corp. and Eagle Plains Resources Enter into an Option Agreement for the Dufferin Project in the Athabasca Basin

6,424 hectare Dufferin Project located approximately 130km northwest of the Key Lake Mines, SaskatchewanFigure 1Project Map reflecting the results of certain historic exploration work on the Project and in the Project area. This information was gathered from historic exploration work conducted on the Project, including from SMDI descriptions and assessment reports filed with the Saskatchewan Governments. The Company has not had a qualified person independently verify this information. Information regarding exploration work in the Project area is not necessarily indicative of the mineralization (if any) present at the Project.VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Refined Metals Corp. (CSE: RMC; OTC: RFMCF; FRA: CWA0) (the “Company”) is pleased to announce that it has entered into an option agreement...

Continue reading

ATHA Energy Announces Appointment of Ryan Gaffney as Senior Vice President, Business Development

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — ATHA Energy Corp. (CSE: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA” or the “Company”), holder of the largest uranium exploration portfolio in two of the highest-grade uranium districts in the world, is pleased to announce that it has appointed Ryan Gaffney as Senior Vice President, Business Development of the Company, effective February 26, 2023. Troy Boisjoli, CEO of ATHA commented, “We are very fortunate to welcome Mr. Gaffney and his decades of capital markets and resource experience to the ATHA team, as we continue to place an emphasis on putting together a world-class team of experienced professionals. Looking ahead, we believe ATHA’s dominant land position in multiple high-grade uranium basins allows us to execute ATHA’s exploration and development strategy from a...

Continue reading

Canoo Successfully Completes First Hiring Milestone and Receives Non-Dilutive Incentives from Oklahoma

Government incentives are a critical part of supporting job growth in advanced manufacturing and other important global technologies Justin, TX, Feb. 27, 2024 (GLOBE NEWSWIRE) — Justin, TX – (February 27, 2024) – Canoo Technologies (NASDAQ:  GOEV), a leading high-tech advanced mobility company, announced it has received its first funding from the State of Oklahoma for successfully achieving an employment milestone from previously announced agreements awarded on workforce and economic development incentives from the state of Oklahoma.   The state is now home to over 20% of Canoo’s total workforce. “We selected the state of Oklahoma as our manufacturing home due to the state’s strong support and hardworking employees.  We are very proud to reach this first hiring milestone and excited to bring high paying advanced manufacturing jobs...

Continue reading

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) —   Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced clinical results from its Phase 1/2 dose escalation study of NT219 in combination with cetuximab in the treatment of patients with recurrent/metastatic head and neck cancer (R/M SCCHN). The data were presented at the European Society of Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Congress 2024 in Paris on Monday, February 26,...

Continue reading

R1 RCM Reports Fourth Quarter and Full Year 2023 Results

MURRAY, Utah, Feb. 27, 2024 (GLOBE NEWSWIRE) — R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups, today announced results for the three months and year ended December 31, 2023. Fourth Quarter 2023 Results:Revenue of $575.1 million, up $41.8 million or 7.8% compared to the same period last year GAAP net income of $1.4 million, compared to a net loss of $36.6 million in the same period last year Adjusted EBITDA of $167.7 million, up $42.1 million or 33.5% compared to the same period last yearFull Year 2023 Results:Revenue of $2,254.2 million, up $447.8 million or 24.8% compared to 2022 GAAP net income of $3.3 million, compared to net loss...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.